| 1 |
31634532 | Impact of obeticholic acid on the lipoprotein profile in patients with non-alcoholic steatohepatitis. | 2020 Jan |
4 |
| 2 |
32118303 | Timing Is Everything: Improving NASH Histology in Clinical Trials Should Not Be Rushed. | 2020 Apr |
1 |
| 3 |
31254596 | Obeticholic acid may increase the risk of gallstone formation in susceptible patients. | 2019 Nov |
2 |
| 4 |
31441502 | Fatigue in Primary Biliary Cholangitis: No Place for Rituximab. | 2019 Nov |
1 |
| 5 |
28746779 | Hepatic farnesoid X receptor protein level and circulating fibroblast growth factor 19 concentration in children with NAFLD. | 2018 Feb |
1 |
| 6 |
29487110 | Farnesoid X Receptor Agonists Obeticholic Acid and Chenodeoxycholic Acid Increase Bile Acid Efflux in Sandwich-Cultured Human Hepatocytes: Functional Evidence and Mechanisms. | 2018 May |
1 |
| 7 |
30026040 | Structural optimization and in vitro profiling of N-phenylbenzamide-based farnesoid X receptor antagonists. | 2018 Aug 7 |
1 |
| 8 |
30254132 | A nonalcoholic fatty liver disease model in human induced pluripotent stem cell-derived hepatocytes, created by endoplasmic reticulum stress-induced steatosis. | 2018 Sep 25 |
1 |
| 9 |
27939613 | Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. | 2017 Mar |
2 |
| 10 |
28805978 | Obeticholic acid, a selective farnesoid X receptor agonist, regulates bile acid homeostasis in sandwich-cultured human hepatocytes. | 2017 Aug |
1 |
| 11 |
27468093 | Obeticholic acid for the treatment of primary biliary cholangitis. | 2016 Sep |
1 |
| 12 |
27743502 | Modeling and Experimental Studies of Obeticholic Acid Exposure and the Impact of Cirrhosis Stage. | 2016 Dec |
2 |
| 13 |
25329562 | The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid. | 2015 Jan |
1 |
| 14 |
26642350 | Therapy of Primary Biliary Cirrhosis: Novel Approaches for Patients with Suboptimal Response to Ursodeoxycholic Acid. | 2015 |
1 |
| 15 |
12749886 | Binding mode of 6ECDCA, a potent bile acid agonist of the farnesoid X receptor (FXR). | 2003 Jun 2 |
1 |